Sharps Technology Inc. (ticker: STSS) is an NASDAQ-listed clinical biotech company. DredgeCap's structured extraction of STSS's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. STSS reported $193K in revenue and -$86.24M for the period ending 2026-03-31, with operating cash flow of -$2.68M. Cash and equivalents stood at $12.32M (up 3.6% year-over-year). Total assets of $181.00M exceed total liabilities of $2.22M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
STSS Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Sharps Technology Inc. (STSS) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.